291 related articles for article (PubMed ID: 17603228)
1. Prescription of nonsteroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: analysis of the present status based on questionnaires obtained from orthopedists in Japan.
Tsumura H; Tamura I; Tanaka H; Chinzei R; Ishida T; Masuda A; Shiomi H; Morita Y; Yoshida M; Kutsumi H; Inokuchi H; Doita M; Kurosaka M; Azuma T
Intern Med; 2007; 46(13):927-31. PubMed ID: 17603228
[TBL] [Abstract][Full Text] [Related]
2. Prescription audit of NSAIDs and gastroprotective strategy in elderly in primary care.
Al Khaja KAJ; Veeramuthu S; Isa HA; Sequeira RP
Int J Risk Saf Med; 2017; 29(1-2):57-68. PubMed ID: 28885223
[TBL] [Abstract][Full Text] [Related]
3. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
;
Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
[TBL] [Abstract][Full Text] [Related]
4. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
[TBL] [Abstract][Full Text] [Related]
5. Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers.
Scheiman J; Isenberg J
Am J Med; 1998 Nov; 105(5A):32S-38S. PubMed ID: 9855174
[TBL] [Abstract][Full Text] [Related]
6. Gastropathy induced by nonsteroidal anti-inflammatory drugs: prescribing patterns among geriatric practitioners.
Pertusi RM; Godwin KS; House JK; Knebl JA; Alexander JH; Rubin BR; Forman MD
J Am Osteopath Assoc; 1999 Jun; 99(6):305-10. PubMed ID: 10405516
[TBL] [Abstract][Full Text] [Related]
7. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
8. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
[TBL] [Abstract][Full Text] [Related]
9. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.
Johnell K; Fastbom J
Clin Drug Investig; 2008; 28(11):687-95. PubMed ID: 18840011
[TBL] [Abstract][Full Text] [Related]
10. [Prevention of Non-steroidal Anti-inflammatory Drug-induced Peptic Ulcers].
Chu SJ; Yoon KT; Kim JS
Korean J Gastroenterol; 2020 Nov; 76(5):232-237. PubMed ID: 33234769
[TBL] [Abstract][Full Text] [Related]
11. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
Barozzi N; Tett SE
Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
[TBL] [Abstract][Full Text] [Related]
12. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database.
Schnitzer TJ; Kong SX; Mavros PP; Straus WL; Watson DJ
Clin Ther; 2001 Dec; 23(12):1984-98. PubMed ID: 11813933
[TBL] [Abstract][Full Text] [Related]
13. Gastroprotection during the administration of non-steroidal anti-inflammatory drugs. A drug-utilization study.
Carvajal A; Arias LH; Vega E; Sánchez JA; RodrÃguez IM; Ortega PG; del Pozo JG
Eur J Clin Pharmacol; 2004 Aug; 60(6):439-44. PubMed ID: 15221157
[TBL] [Abstract][Full Text] [Related]
14. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs.
Sturkenboom MC; Burke TA; Tangelder MJ; Dieleman JP; Walton S; Goldstein JL
Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1137-47. PubMed ID: 14653834
[TBL] [Abstract][Full Text] [Related]
15. [Prevention of NSAID induced gastroduodenal ulcers].
Hansen JM; Bytzer P
Ugeskr Laeger; 2001 Oct; 163(44):6103-5. PubMed ID: 11715151
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitor treatment decreases the incidence of upper gastrointestinal disorders in elderly Japanese patients treated with NSAIDs.
Sakamoto Y; Shimoyama T; Nakagawa S; Mikami T; Fukuda S
Intern Med; 2014; 53(11):1107-11. PubMed ID: 24881732
[TBL] [Abstract][Full Text] [Related]
17. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
18. The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy.
Superceanu B; Veldhuyzen van Zanten S; Skedgel C; Shepherd M; Sketris I
Can J Gastroenterol; 2010 Aug; 24(8):481-8. PubMed ID: 20711527
[TBL] [Abstract][Full Text] [Related]
19. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice. A general practitioner-based survey in France.
Clinard F; Bardou M; Sgro C; Lefevre N; Raphael F; Paille F; Dumas M; Hillon P; Bonithon-Kopp C
Eur J Clin Pharmacol; 2001 Dec; 57(10):737-43. PubMed ID: 11829204
[TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs: an update.
Dajani EZ; Agrawal NM
J Physiol Pharmacol; 1995 Mar; 46(1):3-16. PubMed ID: 7599335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
